A curate’s egg for MorphoSys
Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.
Phase 1 entrants seek improved safety
First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.
Nothing like Hippo for cooling investor enthusiasm
Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.
ASCO Plenary – what Astellas does Keymed might do better
Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.
A changing of the guard in stomach cancer?
Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.
ASCO Plenary – Gilead and Arcus pedal hard with TIGIT
A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.
